Update on the merger approval process for the combination of Novozymes and Chr. Hansen: South Korean merger approval granted

December 20, 2023 Please see attachment. Contact informationInvestor RelationsDisa Tuominen +45 6038 5826dkditu@chr-hansen.comPress RelationsSanne Seyer-Hansen +45 6038 6207dksash@chr-hansen.comAttachment 2023_South Korean merger approval granted
Comunicato Precedente

next
Comunicato Successivo

next
Preferisci Informazione.News su Google

December 20, 2023


Please see attachment.


Contact information

Investor Relations
Disa Tuominen
+45 6038 5826
dkditu@chr-hansen.com

Press Relations
Sanne Seyer-Hansen
+45 6038 6207
dksash@chr-hansen.com

Attachment

  • 2023_South Korean merger approval granted

Per maggiori informazioni
Sito Web
chr-hansen.com

Ufficio Stampa

 Nasdaq GlobeNewswire (Leggi tutti i comunicati)
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti

Allegati
Slide ShowSlide Show
Non disponibili
;